Semaglutide 1 mg demonstrated statistically significant and superior improvement in maximum walking distance by 13% over placebo in adults with type 2 diabetes and symptomatic PAD 1Based on STRIDE trial data, presented at the American College of Cardiology's (ACC) Annual Scientific Session and Expo while simultaneously published today in The Lancet , Novo Nordisk submitted a label extension application accepted for review by the FDAApproximately 12 million people in the United States are impacted by PAD, a form of atherosclerotic disease, and one in four also have type 2 diabetes2,3PLAINSBORO, N.J., March 29, 2025 /PRNewswire/ -- Novo Nordisk today presented results from STRIDE, its phase 3b trial investigating the effects of once-weekly Ozempic® (semaglutide) injection 1 mg in adults with type 2 diabetes and early-stage symptomatic PAD1, at the American College of Cardiology's (ACC) Annual Scientific Session and Expo. The results were presented during a late-breaking clinical trial session and highlighted at an official ACC press conference. In addition, the analysis was also simultaneously published today in The Lancet.The double-blind, randomized, placebo-controlled STRIDE trial, which enrolled 792 adults with type 2 diabetes and symptomatic PAD, achieved its primary endpoint, with semaglutide 1 mg demonstrating a 13% superior improvement in maximum walking distance (estimated treatment ratio [ETR] vs placebo, 1.13; 95% confidence interval [CI], 1.06 to 1.21; p=0.0004) and a clinically meaningful median treatment difference of 26.4 meters (95% CI, 11.8 to 40.9; approximately 87 feet, or about a third the length of an American football field) on a 12% incline, compared to placebo at 52 weeks. The trial also demonstrated superiority to placebo for all confirmatory secondary outcomes assessed, including pain-free walking distance (ETR vs placebo 1.11; 95% CI, 1.03 to 1.20; p=0.0046) and Vascular Quality of Life Questionnaire-6 (VascuQoL-6) (estimated treatment difference vs placebo 1.00; 95% CI, 0.48 to 1.52; p=0.011) at 52 weeks.1,4"Peripheral artery disease (PAD) may cause severe symptoms, physical limitations, and a diminished quality of life, often making even short walks—such as retrieving the mail—challenging. In individuals with PAD and diabetes, the disease can be even more severe, affecting small blood vessels and limiting the effectiveness of revascularization procedures and other treatments. Semaglutide 1 mg is the first medication in over two decades to show meaningful improvements in functional capacity and quality of life, which could address a critical unmet need for those with both PAD and type 2 diabetes," said Marc P

VANCOUVER, BC, Jan. 27, 2025 /PRNewswire/ - The U.S. wound and tissue management market is a highly competitive industry with multiple competing segments positioned as substitutes for one another. This intense competition will limit market growth despite the otherwise strong presence of major drivers of growth including demographic factors, rising rates of diabetes, obesity, and favorable Medicare policies. Competition is further driven by a constant need to innovate to avoid the commoditization of products within the market which would lead to price competition and slim profit margins. The US market for wound and tissue management is expected to grow to reach nearly $16 billion USD by 2030